SYNTHETIC PEPTIDE ANALOGS OF CROSS-LINKED N-TELOPEPTIDES OF TYPE I COLLAGEN

Abstract: Synthetic linear peptides embodied by Xaa-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly which mimic the epitope recognized by mAb 1H11 (ATCC No. HB 10611) in cross-linked N-telopeptides of type I collagen (NTx).

Description: SYNTHETIC PEPTIDE ANALOGS OF CROSS-LINKED N-TELOPEPTIDES OF TYPE I COLLAGEN Field of the Invention This invention relates to immunoassays and provides a synthetic peptide that acts as an immunoreactive analog of the natural cross-linked amino-terminal telopeptide of type I collagen. Background of the Invention Cross-linked N-telopeptides of type I collagen (NTx) are excreted in urine as end-products of the process of bone resorption. These metabolites can be measured by immunoassay to provide an accurate and specific index of bone resorption activity, for example, using the monoclonal antibody (mAb) IHl l produced by hybridoma IHl l (ATCC No. HB 10611). The epitope recognized by mAb IHl l is embodied in forms of the excreted cross-linked N-telopeptides that include the collagen α2(I) N-telopeptide sequence Gln-Tyr-Asp-Gly-K-Gly-Val-Gly, together with a linked second telopeptide from either αl(I) or α2(I), wherein K is embodied in the cross-link. The predominant cross-linked NTx metabolite excreted in urine is shown: Asp-Glu-K-Ser-Thr-Gly-Gly αl ( I ) I Gln-Tyr-Asp-Gly-K-Gly-Val-Gly <x2 ( I ) I K wherein K is hydroxylysyl pyridinoline or lysyl pyridinoline, and I K I K Gin is glutamine (Q) or wholly cyclized pyrrolidone carboxylic acid (5-oxo- 2-pyrrolidinecarboxylic acid, i.e., pyroglutamic acid) (J). Linear peptides synthesized to match the human αl(l) or α2(l) N-telopeptide sequences, and in which K is simply lysine, are respectively not recognized or recognized very weakly by mAb IHl l. WO 91/08478; Hanson et al., Journal of Bone and Mineral Research, 7(11):1251-1258, 1992. The hybridoma cell line that produces the mAb IHl 1 was deposited on November 20, 1990, at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852, USA, under accession number HB 10611. Summary of the Invention Here we describe synthetic peptides that exhibit strong binding to mAb IHl l. The subject peptides are embodied by: Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly, wherein Gin is pyrrolidone carboxylic acid, wherein residue Xaa in position 2 is Asp, Glu, or other α-amino acid with a negatively charged side chain (R group), and wherein the structure of residue Xaa in position 5 is such that the peptide mimics features of the cross-linked NTx conformation and chemistry such that the peptide binds to mAb IHll. In a first embodiment, Xaa in position 5 is selected from among Asp, Glu, and other negatively charged amino acids. In a second embodiment, Xaa in position 5 is selected from among Pro, Nva (norvaline), Trp, His, and conservative substitutions therefor that provide the requisite degree of binding to mAb IHl 1. In a third embodiment, Xaa in position 5 bears a thiol group, in which case the peptides may dirnerize via a cystine bridge. In a fourth embodiment, Xaa in position 5 bears an amino or thiol group that is conjugated to a carrier molecule or insoluble material. These molecular mimics of the cross-linked NTx epitope are conveniently synthesized for use as immunoassay standards, solid-phase coating antigens, immunogens, and other conjugated molecular structures for measuring NTx in biological samples. Detailed Description of the Preferred Embodiment The invention provides synthetic linear peptides which mimic the epitope recognized by mAb IHl 1 in cross-linked NTx. The subject peptides are embodied by the generic formula Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly, wherein Gin is pyrolidone carboxylic acid, residue Xaa in position 3 is negatively charged, and the structure of residue Xaa in position 5 is such that the peptide mimics the NTx conformation and chemistry to the extent that the peptide binds to mAb IHl 1. Representative peptides designated by SEQ ID NOS: 1-59 are shown in the Table below, along with their relative binding affinities for mAb IHl l. Starting with the observation that the synthesized α2(I) N-telopeptide sequence Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly (SEQ LD NO: 9) is a very weak binding partner for mAb IHl l, a series of peptides was synthesized in which certain amino acids were substituted for lysine (Lys). Improved binding to mAb IHl l was especially evident when the positively charged Lys residue in position 5 was replaced with amino acids having negatively charged side chains, particularly glutamic acid (Glu) (SEQ LD NO:4) and to a lesser degree aspartic acid (Asp) (SEQ LD NOS:3 and 31). For example, the peptide Gln-Tyr-Asp-Gly-Glu-Gly-Val-Gly (synthesized so that Gin is pyroglutamic acid) had a binding affinity for mAb IHl 1 comparable to that of the cross-linked NTx antigen. The mAb IHll inhibition curves for NTx (derived from either urine or bone) and Gln-Tyr-Asp-Gly-Glu-Gly-Val-Gly are essentially parallel, indicating that the synthetic peptide mimics the natural epitope. Such preferred embodiments of the subject synthetic peptides bind to mAb IHl l at a substantially equimolar extent as does the cross-linked NTx metabolite (shown above) in antibody inhibition assays. Available data suggest that the core sequence, Gln-Tyr-Asp-Gly-Glu-Gly-Val- Gly, represents the requisite size for presenting the epitope recognized by mAb IHl 1. Substituting Gly-Gly- for the N-terminal Gin- (SEQ LD NO:41), or adding either -Lys or -Gly-Lys-Leu to the C-terminus (SEQ LD NOS:40 and 42), prevents mAb IHll binding. The degrees to which individual amino acids in the core sequence are considered essential for mAb IHl 1 epitope binding are as follows. Binding to mAb IHl l occurs when the N-terminal Gin (position 1) is in the cyclized form, pyrrolidine carboxylic acid (J), as occurs naturally in collagen chains. The core sequence can be formed with pyrrolidone carboxylic acid in position 1 by initially sequencing the core sequence with Glu in position 1, followed by autoclaving the peptide. Autoclaving causes the cyclization of Glu to pyrrolidone carboxylic acid. The Tyr residue in position 2 is an essential feature, as iodination of Tyr or substitution with Phe (SEQ LD NO:36) in this position blocks mAb IHl 1 binding. The Asp residue in position 3 is also considered important, as substituents that eliminate the negative charge at this position block mAb IHl 1 binding (based upon binding studies with NTx of modified structure from animal species other than human). However, the Asp in position 3 may be replaced by Glu (SEQ LD NO:30) or other α-amino acid residue bearing a negatively charged R group. The Gly residue in position 4 is important, as the conversative substitution of either Val (SEQ LD NO:37) or Ala (SEQ LD NO:27) at this position substantially eliminates mAb IHll binding affinity. The Gly residues at positions 6 and 8 are equally important, as various substitutions at these positions, including Ala, Val, Leu, Pro, and Cys, lead to loss of mAb IHl 1 binding affinity. (See SEQ LD NOS:28, 35, 46, 49, 52, 54, and 56.) The Val residue at position 7 is important, as conservative substitutions of other hydrophobic substituents, such as Leu (SEQ LD NO: 29) or He (SEQ LD NO:55), eliminate the requisite binding of mAb IHl 1. Accordingly, the invention provides, in a first embodiment, a peptide that binds to mAb IHll, comprising Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly (SEQ LD NO:60), wherein Gin is pyrrolidone carboxylic acid, Xaa in position 3 is a negatively charged amino acid residue, and Xaa in position 5 is also an amino acid with a negatively charged R group. A suitable amino acid with a negatively charged R group is selected from among Glu, Asp, and other natural and synthetic α-amino acids which bear a negatively charged R group such as a carboxyl, sulfate, or phosphate group. Representative examples include α-aminoadipic acid (SEQ LD NO: 34) and cysteic acid (SEQ LD NO:26). In a second embodiment, the Xaa residue in position 5 is selected from among Pro, Tip, Nva, and His (SEQ LD NO:61) or conservative substitutions therefor that afford a requisite degree of mAb IHl 1 binding. Representative amino acids with a nonpolar R group include Pro (SEQ LD NO: 13), Trp (SEQ LD NO: 19), norvaline (SEQ LD NO: 38), and other natural and synthetic α-amino acids which bear a nonpolar R group such as characterize Ala, He, Leu, Met, Phe, Pro, Trp, and Val. The substitution of His at position 5 (SEQ LD NO: 7) provided a more limited degree of IHl 1 binding. Other natural and synthetic α-amino acids bearing positively charged R groups can be conveniently synthesized and tested pursuant to this disclosure. Among the tested amino acids with a polar but uncharged R group, Cys in position 5 (SEQ LD NO:2) provided excellent binding to mAb IHll. It is contemplated that other natural and synthetic α-amino acids which bear a polar but uncharged R group such as characterize Asn, Cys, Gin, Gly, Ser, Thr, and Tyr may also be suitable. Representative examples include pyridinylalanine (SEQ ID NO: 62) (Bachem) and other α-amino acids wherein the R group has a pyridine ring. Cysteine and other thiol bearing α-amino acids are particularly preferred embodiments in terms of the degree of mAb IHll binding. Thus, in a third embodiment, the invention provides a peptide that binds to mAb IHll, comprising Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly (SEQ LD NO:63), wherein Gin is pyrrolidone carboxylic acid, Xaa in position 3 is a negatively charged amino acid residue, and Xaa in position 5 is an α-amino acid bearing a thiol group. Representative examples include cysteine (SEQ LD NO: 2), homocysteine (SEQ LD NO: 64), and related residues in which R contains 0-3 carbon atoms. In the presence of atmospheric oxygen this peptide forms disulfide-bonded dimers that mimic the NTx epitope as follows: Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Giy I s Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly. Each of the residues Xaa in position 5 may be the same or a different α-amino acid bearing a side chain (R) with a thiol group. In a fourth embodiment, the natural epitope embodied in urinary NTx is mimicked by conjugating the synthetic peptide Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly (SEQ LD NO:65) to either a solute or an insoluble material. Here, the Gin and the Xaa in position 3 are as defined above, and the Xaa in position 5 is an α-amino acid bearing a side chain amino or thiol group. For example, Xaa in position 5 may be lysine (SEQ LD NO: 9) with an epsilon amino group, in which case conjugation to the solute or insoluble material is through the amino group, for example by glutaraldehyde using standard procedures. Representative Xaa residues for this purpose are lysine and cysteine (SEQ LD NO:2), and representative linking agents, for conjugation to, e.g., bovine serum albumin, are glutaraldehyde and m-malieimidobenzoyl-N- hydroxysuccinimide ester (MBS), respectively. By solute is meant a molecular substance dissolved in aqueous solution. Representive solutes for this purpose include proteins, such as keyhole limpet hemocyanin (KLH), albumin, and enzymes, peptides such as Gln-Tyr-Asp-Gly-Cys-Gly-Val-Gly (or Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly), and other soluble molecules such as biotin, avidin, and fluorescent and chemiluminescent moieties. Representative insoluble materials include latex particles, dipsticks, microtiter wells, and other substrata used in heterogeneous immunoassays. Once conjugated by such a standard linking agent to, for example, KLH, the antibody- binding affinity of the Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly peptide for mAb IHl l is increased about 50-fold, approximating the binding affinity of the natural epitope. Such a conjugate can be used in solution as a competing antigen or as a coating agent for solid surfaces, for example, to coat wells in a microtiter-plate kit or latex or other particles in automated assay systems. Accordingly, this fourth embodiment of the invention provides a conjugated peptide that binds to mAb IHl 1, comprising: Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly I R wherein Gin is pyrrolidone carboxylic acid, Xaa in position 3 is a negatively charged amino acid residue, Xaa in position 5 is an amino acid residue bearing an amino group or thiol group, and R is either a solute or an insoluble material conjugated through the amino group or thiol group to residue Xaa in position 5. EXAMPLE Testing synthetic peptides for binding to mAb IHl 1. The synthetic peptides of the present invention are prepared by methods well known in the art, for example as summarized in A. P. Gloor, et al., Synthesis Notes, Novabiochem Catalog and Peptide Synthesis Handbook, La Jolla, CA, pp. S1-S5, 1994-1995. For the following experiment, synthetic peptides were purchased from an outside vendor, or made in house using the Symphony/Multiplex (TM) multiple peptide synthesizer from Rainin Instrument Co. (Woburn, MA) Less than 10% of the peptides were tested for purity. Those that were examined were found to be greater than 80% pure by reverse phase HPLC. Most of the peptides made have a single aromatic amino acid, tyrosine. We assumed the extinction coefficient of tyrosine at 280 nanometers to be equal to the extinction coefficient of the synthetic peptides. If the peptides had additional aromatic residues, logical adjustments were made to the extinction coefficient. Generally, a milligram per mL solution of the peptide was made in PBS. The absorbence at A280 was read and the concentration confirmed. Dilutions of the peptide were then made in a buffer such as OSTEOMARK (TM) calibrator diluent (OSTEOMARK Assay, Ostex International, Seattle, WA). Working strength concentrations were between 10 and 0.01 micrograms per milliliter. To test the apparent affinity of the synthetic peptides for mAb IHl l, the OSTEOMARK assay was run using OSTEOMARK kits and components, including monoclonal antibody IHl l. A standard curve was run using OSTEOMARK calibrators. Peptide samples were generally tested at 10, 3, 1, and down to .01 μG per mL. The standard OSTEOMARK curve was generated using a four parameter logistic curve fit program (MedData Inc., N.Y., NY). Peptide values were back fit into the standard curve and values were reported in picomoles Bone Collagen Equivalents (BCE)/mL (which equals nanomolar BCE, or nM BCE). As not all peptides that competed for IHl 1 showed a linear response, values between 0.5 and 1 optical density units were taken and averaged. Representative peptides made and tested are shown in the following Table. Values in the Table are reported as the number of nanomoles of BCE equivalent to a microgram of a given peptide. Antibody binding values below 500 nMole BCE were considered to be commercially insignificant. TABLE 1 Peptide binding to mAb IHll is expressed in the following units: 1 μg synthetic peptide = X nmole BCE, where X is the value in the Table. For comparison, the native sequence, JYDGKGVG (SEQ ID NO:9), gave an X value of 100 in this assay. 2 X = cysteic acid (2-amino-3-sulfopropanoic acid). That is, cysteine with a su-fite (-S0 3 "2 ) group substituted for the normal mercapto (-SH) group, preventing disulfide bridges. 3 The sequence EYDGEGVG is not recognized by IHl 1. Here, by autoclaving this peptide under conditions that convert the glutamic acid in position 1 into pyroglutamic acid, substantial increase in IHll binding resulted. Therefore, the N terminus pyroglutamic acid is part of the epitope. 4 X = α-aminoadipic acid (2-amino hexanedioic acid), in which the side chain amino group of lysine is replaced by a negatively charged carboxyl group. 5 X = Norvaline. 6 X = G-NH 2 . The carboxyl group of the Gly residue in position 8 is normally exposed (not in peptide bond). Here, an amino group was added to the carboxyl group (to make 1,2- diaminoacetaldehyde), which prevented recognition. Therefore, the free carboxyl group is considered part of the epitope. In summary, the invention provides synthetic peptides that mimic the complex epitope of cross-linked human bone and urinary NTx recognized immunochemically, for example, by mAb IHll. These synthetic peptides can be used to simplify the manufacture of immunoassay kits and other commercial formats, so as to provide reproducible standards for calibration and novel synthetic antigen formulations, for use for example in homogeneous immunoassay systems such as disclosed in U.S. Patents No. 5,212,064 and No. 5,362,625 (Microgenics Corporation) and other automated assay systems. Such usage of the subject synthetic peptides as immunoassay standards, solid-phase coating antigens, immogens, and other conjugated molecular structures for immunoassays follow from conventional information available to those skilled in the art, for example, as disclosed in: Principles and Practice of Immunoassay, C. P. Price and D. J. Newman (Eds.), Stockton Press, NY, 1991. While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. 7 X = 4-hydroxyproline. 8 nd = not determined. 9 X = Biotinolated lysine (K). 10 X = Biotinolated cysteine (C). SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Eyre, David R. Clemens, J. Daniel Ochs, Vincent W. (ii) TITLE OF INVENTION: Synthetic Peptide Analogs of NTx (iii) NUMBER OF SEQUENCES: 74 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Christensen O'Connor Johnson & Kindness PLLC (B) STREET: 1420 Fifth Avenue, Suite 2800 (C) CITY: Seattle (D) STATE: Washington (E) COUNTRY: U.S.A. (F) ZIP: 98101 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/446,206 (B) FILING DATE: 19-MAY-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Shelton, Dennis K. (B) REGISTRATION NUMBER: 26,997 (C) REFERENCE/DOCKET NUMBER: WROS19489 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 206 224 0718 (B) TELEFAX: 206 224 0779 (2) INFORMATION FOR SEQ ID Nθ:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide RECTIFIED SHEET (RULE 91) ISA/EP (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: Xaa Tyr Asp Gly Ala Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE ' : (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Xaa Tyr Asp Gly Cys Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: RECTIFIED SHEET (RULE 91) Xaa Tyr Asp Gly Asp Gly Val Gly 1 5 " (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: : Xaa Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Xaa Tyr Asp Gly Phe Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear RECTIFIED SHEET (RULE 91) ISA/EP (ii) MOLECULE TYPE: ' peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Xaa Tyr Asp Gly Gly Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Xaa Tyr Asp Gly His Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid RECTIFIED SHEET (RULE 91) (xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 8 : Xaa Tyr Asp Gly He Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid /note=. "alpha2 (I) type I collagen" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Xaa Tyr Asp Gly Lys Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Xaa Tyr Asp Gly Leu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids RECTIFIED SHEET (RULE 91) (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Xaa Tyr Asp Gly Met Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Xaa Tyr Asp Gly Asn Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature RECTIFIED SHEET (RULE 91) (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Xaa Tyr Asp Gly Pro Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Xaa Tyr Asp Gly Gin Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Xaa Tyr Asp Gly Arg Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:16: RECTIFIED SHEET (RULE 91) ISA/E ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH': 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Xaa Tyr Asp Gly Ser Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) ' STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Xaa Tyr Asp Gly Thr Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal RECTIFIED SHEET (RULE 91) ISA/EP ( ix) FEATURE: (A) NAME/KEY: -misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Xaa Tyr Asp Gly Val Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Xaa Tyr Asp Gly Trp Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 ammo acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Xaa Tyr Asp Gly Tyr Gly Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Xaa Tyr Asp Gly Arg Gly Val Ala 1 5 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Xaa Tyr Asp Gly Glu Gly Val Leu 1 5 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide RECTIFIED SHEET (RULE 91) ISA/EP (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Xaa Tyr Asp Gly Glu Gly Val 1 5 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Xaa Tyr Asp Gly Glu 1 5 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: RECTIFIED SHEET (RULE 91) ISA/EP Xaa Asp Gly Glu Gly Val 1 5 ■ (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1, 5..6 (D) OTHER INFORMATION: Xaa in position 1 is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa in position 5 is cysteic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Xaa Tyr Asp Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Xaa Tyr Asp Ala Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:28: RECTIFIED SHEET (RULE 91) ISA/EP ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 8 "" amino acids ( B ) TYPE : amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Xaa Tyr Asp Gly Glu Ala Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Xaa Tyr Asp Gly Glu Gly Leu Gly 1 5 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal RECTIFIED SHEET (RULE 91) ISA/EP (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Xaa Tyr Glu Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Xaa Tyr Asp Gly Asp Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Xaa Tyr Glu Gly Asp Glu Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP ( 2 ) INFORMATION FOR SEQ ID NO : 33 : (i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is Glu converted (by autoclaving the peptide) to pyroglutamic acid ( i) SEQUENCE DESCRIPTION: SEQ ID NO:33: Xaa Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is 2-aminoadipic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Xaa Tyr Asp Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid RECTIFIED SHEET (RULE 91) (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Xaa Tyr Asp Gly Glu Gly Val Val 1 5 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Xaa Phe Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 RECTIFIED SHEET (RULE 91) ISA/EP (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Xaa Tyr Asp Val Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Val is norvaline (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Xaa Tyr Asp Gly Val Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Xaa Tyr Asp Gly Glu Gly Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP ( 2 ) INFORMATION FOR ' SEQ ID NO : 0 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 9 amino acids (B ) TYPE : amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Xaa Tyr Asp Gly Glu Gly Val Gly Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Gly Gly Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal ( ix ) FEATURE : (A) NAME/KEY: misc-feature RECTIFIED SHEET (RULE 91) ISA/EP (B) LOCATION: 1 (D) OTHER' INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Xaa Tyr Asp Gly Glu Gly Val Gly Gly Lys Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: Ser Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa s pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 8 (D) OTHER INFORMATION: Xaa is 1,2-diaminoacetaldehyde (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: Xaa Tyr Asp Gly Glu Gly Val Xaa 1 5 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: RECTIFIED SHEET (RULE 91) ISA/EP (A) LENGTH : 8 amino acids (B) TYPE: : amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: Gly Val Gly Cys Gly Asp Tyr Gin 1 5 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 46: Xaa Tyr Asp Gly Glu Val Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: RECTIFIED SHEET (RULE 91) A E Xaa Tyr Asp Gly Glu Gly Gly Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: Xaa Tyr Asp Gly Glu Gly Ala Gly 1 5 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: Xaa Tyr Asp Gly Glu Gly Val Ala 1 5 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino- acid (C) STRANDEDNESS: RECTIFIED SHEET (RULE 91) ISA/EP (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: His Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Pro Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa s pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: Xaa Tyr Asp Gly Glu Cys Gly Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids RECTIFIED SHEET (RULE 91) ISA/EP (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: Xaa Val Gly Glu Gly Asp Tyr Asn 1 5 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: Xaa Tyr Asp Gly Glu Gly Val Pro 1 5 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature RECTIFIED SHEET (RULE 91) ISA/EP (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: Xaa Tyr Asp Gly Glu Gly He Gly 1 5 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: Xaa Tyr Asp Gly Glu Gly Val Cys 1 5 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is 4Hyp (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: Xaa Tyr Asp Gly Glu Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:58: RECTIFIED SHEET (RULE 91) ISA/EP ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 8 ' amino acids ( B) TYPE : amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is biotinylated Lys (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: Xaa Tyr Asp Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is biotinylated Cys (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: Xaa Tyr Asp Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids RECTIFIED SHEET (RULE 91) ISA/EP (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 60: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is Pro, Trp, Nva, or His RECTIFIED SHEET (RULE 91) ISA/EP ( i ) SEQUENCE DESCRIPTION : SEQ ID NO : 61 : Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is pyridinylalanine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature RECTIFIED SHEET (RULE 91) ISA/EP (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is an alpha-amino acid residue bearing a thiol group (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is homocysteine ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 64: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide RECTIFIED SHEET (RULE 91) ISA/EP (v) FRAGMENT TYPE : ' N-terminal ( ix ) FEATURE : (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is an alpha-amino acid bearing a side chain amino or thiol group (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 ( D) OTHER INFORMATION : Xaa is pyroglutamic acid ( ix ) FEATURE : (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is glutamine (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP ( 2 ) INFORMATION FOR SEQ ID NO : 67 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 8 amino acids ( B) TYPE : amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is aspartic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature RECTIFIED SHEET (RULE 91) ISA/EP (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is cysteic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is alpha-aminoadipic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 RECTIFIED SHEET (RULE 91) ISA/EP ( D) OTHER INFORMATION : Xaa is pyroglutamic acid (ix) FEATURE : (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is proline (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is tryptophan (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear RECTIFIED SHEET (RULE 91) (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is norvaline (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is histidine (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP (2) INFORMATION FOR SEQ " ID NO:74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (v) FRAGMENT TYPE: N-terminal (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 1 (D) OTHER INFORMATION: Xaa is pyroglutamic acid (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 3 (D) OTHER INFORMATION: Xaa is a negatively charged amino acid residue (ix) FEATURE: (A) NAME/KEY: misc-feature (B) LOCATION: 5 (D) OTHER INFORMATION: Xaa is histidine (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: Xaa Tyr Xaa Gly Xaa Gly Val Gly 1 5 RECTIFIED SHEET (RULE 91) ISA/EP

Claims: The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. A peptide that binds to the antibody obtainable from ATCC HB 10611 , the peptide consisting of: Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly wherein Gin is pyrrolidone carboxylic acid, Xaa in position 3 is a negatively charged amino acid, and Xaa in position 5 is either a negatively charged amino acid, or is selected from among Pro, Trp, Nva, and His, or is an amino acid bearing a thiol group, or is Xaa-R wherein Xaa is an amino acid bearing an amino or thiol group and R is a solute or insoluble material conjugated through the amino or thiol group to Xaa. 2. The peptide of claim 1, wherein Xaa in position 3 is Glu, Asp, cysteic acid, or α-aminoadipic acid. 3. The peptide of claim 1, wherein Xaa in position 5 is a negatively charged amino acid (SEQ LD NO: 60). 4. The peptide of claim 3 wherein Xaa in position 5 is Glu (SEQ LD NO:66), Asp (SEQ ID NO: 67), cysteic acid (SEQ LD NO: 68), or α- aminoadipic acid (SEQ LD NO: 69). 5. The peptide of claim 1, wherein Xaa in position 5 is selected from among Pro (SEQ LD NO:70), Tφ (SEQ LD NO:71), Nva (SEQ LD NO:72), and His (SEQ LD NO:73). 6. The peptide of claim 1, wherein Xaa in position 5 is an α-amino acid bearing a thiol group (SEQ LD NO:63). 7. The peptide of claim 6, wherein Xaa in position 5 is cysteine (SEQ LD NO:74) or homocysteine (SEQ LD NO:64). 8. A dimer of the peptide of claim 6, the dimeric peptide consisting of: RECTIFIED SHEET (RULE 91) Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly I s Gln-Tyr-Xaa-Gly-Xaa-Gly-Val-Gly. 9. The dimeric peptide of claim 8, wherein each Xaa in position 5 is independently cysteine or homocysteine. 10. A peptide of claim 1, consisting of: Gln-Tyr-Xaa-Gly -Xaa-Gly-Val-Gly I R wherein Xaa in position 5 is an amino acid residue bearing an amino or thiol group, and R is a solute conjugated through the amino or thiol group to the Xaa. 11. The peptide of claim 10, wherein the solute is a protein or peptide. 12. The peptide of claim 1, consisting of: Gln-Tyr-Xaa-Gly Xaa-Gly-Val-Gly I R wherein Xaa in position 5 is an amino acid residue bearing an amino or thiol group, and R is an insoluble material conjugated through the amino or thiol group to the Xaa. RECTIFIED SHEET (RULE 91)

Inventors: CLEMENS DANIEL J, EYRE DAVID R, OCHS VINCENT W, CLEMENS, J., DANIEL, EYRE, DAVID, R., OCHS, VINCENT, W.
Applicants: CLEMENS DANIEL J, EYRE DAVID R, OCHS VINCENT W, OSTEX INTERNATIONAL INC, WASHINGTON RES FOUND, CLEMENS, J., DANIEL, EYRE, DAVID, R., OCHS, VINCENT, W., OSTEX INTERNATIONAL, INC., WASHINGTON RESEARCH FOUNDATION
Application year: 1996
Main classification: C07K14
IPC codes: C07K7, C07K14